BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

600 related articles for article (PubMed ID: 28558704)

  • 1. Genome-wide network-based pathway analysis of CSF t-tau/Aβ1-42 ratio in the ADNI cohort.
    Cong W; Meng X; Li J; Zhang Q; Chen F; Liu W; Wang Y; Cheng S; Yao X; Yan J; Kim S; Saykin AJ; Liang H; Shen L;
    BMC Genomics; 2017 May; 18(1):421. PubMed ID: 28558704
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genome-wide association reveals genetic effects on human Aβ42 and τ protein levels in cerebrospinal fluids: a case control study.
    Han MR; Schellenberg GD; Wang LS;
    BMC Neurol; 2010 Oct; 10():90. PubMed ID: 20932310
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genome-wide association study of CSF biomarkers Abeta1-42, t-tau, and p-tau181p in the ADNI cohort.
    Kim S; Swaminathan S; Shen L; Risacher SL; Nho K; Foroud T; Shaw LM; Trojanowski JQ; Potkin SG; Huentelman MJ; Craig DW; DeChairo BM; Aisen PS; Petersen RC; Weiner MW; Saykin AJ;
    Neurology; 2011 Jan; 76(1):69-79. PubMed ID: 21123754
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genome-wide association and interaction studies of CSF T-tau/Aβ
    Li J; Zhang Q; Chen F; Meng X; Liu W; Chen D; Yan J; Kim S; Wang L; Feng W; Saykin AJ; Liang H; Shen L;
    Neurobiol Aging; 2017 Sep; 57():247.e1-247.e8. PubMed ID: 28641921
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genetic loci associated with Alzheimer's disease and cerebrospinal fluid biomarkers in a Finnish case-control cohort.
    Elias-Sonnenschein LS; Helisalmi S; Natunen T; Hall A; Paajanen T; Herukka SK; Laitinen M; Remes AM; Koivisto AM; Mattila KM; Lehtimäki T; Verhey FR; Visser PJ; Soininen H; Hiltunen M
    PLoS One; 2013; 8(4):e59676. PubMed ID: 23573206
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An Integrated Bioinformatics Approach for Identifying Genetic Markers that Predict Cerebrospinal Fluid Biomarker p-tau181/Aβ1-42 Ratio in ApoE4-Negative Mild Cognitive Impairment Patients.
    Sun Y; Bresell A; Rantalainen M; Höglund K; Lebouvier T; Salter H;
    J Alzheimers Dis; 2015; 45(4):1061-76. PubMed ID: 25720397
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Social Networks and Cerebrospinal Fluid Biomarkers of Alzheimer's Disease Pathology in Cognitively Intact Older Adults: The CABLE Study.
    Ma YH; Wang YY; Tan L; Xu W; Shen XN; Wang HF; Hou XH; Cao XP; Bi YL; Dong Q; Yang JL; Yu JT
    J Alzheimers Dis; 2021; 81(1):263-272. PubMed ID: 33749650
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects.
    Shaw LM; Vanderstichele H; Knapik-Czajka M; Clark CM; Aisen PS; Petersen RC; Blennow K; Soares H; Simon A; Lewczuk P; Dean R; Siemers E; Potter W; Lee VM; Trojanowski JQ;
    Ann Neurol; 2009 Apr; 65(4):403-13. PubMed ID: 19296504
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quantitative Genetics Validates Previous Genetic Variants and Identifies Novel Genetic Players Influencing Alzheimer's Disease Cerebrospinal Fluid Biomarkers.
    Ramos de Matos M; Ferreira C; Herukka SK; Soininen H; Janeiro A; Santana I; Baldeiras I; Almeida MR; Lleó A; Dols-Icardo O; Alcolea D; Benussi L; Binetti G; Paterlini A; Ghidoni R; Nacmias B; Meulenbroek O; van Waalwijk van Doorn LJC; Kuiperi HBJ; Hausner L; Waldemar G; Simonsen AH; Tsolaki M; Gkatzima O; Resende de Oliveira C; Verbeek MM; Clarimon J; Hiltunen M; de Mendonça A; Martins M
    J Alzheimers Dis; 2018; 66(2):639-652. PubMed ID: 30320580
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genetic variants of GSK3B are associated with biomarkers for Alzheimer's disease and cognitive function.
    Kettunen P; Larsson S; Holmgren S; Olsson S; Minthon L; Zetterberg H; Blennow K; Nilsson S; Sjölander A
    J Alzheimers Dis; 2015; 44(4):1313-22. PubMed ID: 25420549
    [TBL] [Abstract][Full Text] [Related]  

  • 11. What are the Most Frequently Impaired Markers of Neurodegeneration in ADNI Subjects?
    Andriuta D; Moullart V; Schraen S; Devendeville A; Meyer ME; Godefroy O;
    J Alzheimers Dis; 2016; 51(3):793-800. PubMed ID: 26923012
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of CSF markers and semi-quantitative amyloid PET in Alzheimer's disease diagnosis and in cognitive impairment prognosis using the ADNI-2 database.
    Ben Bouallègue F; Mariano-Goulart D; Payoux P;
    Alzheimers Res Ther; 2017 Apr; 9(1):32. PubMed ID: 28441967
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CSF biomarkers and amyloid PET: concordance and diagnostic accuracy in a MCI cohort.
    Spallazzi M; Barocco F; Michelini G; Immovilli P; Taga A; Morelli N; Ruffini L; Caffarra P
    Acta Neurol Belg; 2019 Sep; 119(3):445-452. PubMed ID: 30847669
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multiple Effect of APOE Genotype on Clinical and Neuroimaging Biomarkers Across Alzheimer's Disease Spectrum.
    Liu Y; Tan L; Wang HF; Liu Y; Hao XK; Tan CC; Jiang T; Liu B; Zhang DQ; Yu JT;
    Mol Neurobiol; 2016 Sep; 53(7):4539-47. PubMed ID: 26298664
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Markers of neuroinflammation associated with Alzheimer's disease pathology in older adults.
    Popp J; Oikonomidi A; Tautvydaitė D; Dayon L; Bacher M; Migliavacca E; Henry H; Kirkland R; Severin I; Wojcik J; Bowman GL
    Brain Behav Immun; 2017 May; 62():203-211. PubMed ID: 28161476
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Self-reported traumatic brain injury and in vivo measure of AD-vulnerable cortical thickness and AD-related biomarkers in the ADNI cohort.
    Wang ML; Wei XE; Yu MM; Li PY; Li WB;
    Neurosci Lett; 2017 Aug; 655():115-120. PubMed ID: 28689050
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alzheimer's disease susceptibility locus in CD2AP is associated with increased cerebrospinal fluid tau levels in mild cognitive impairment.
    Xue YY; Chen YH; Lin RR; Huang HF; Wu ZY; Tao QQ;
    Neurosci Lett; 2022 Feb; 771():136419. PubMed ID: 34958910
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Concordance and Diagnostic Accuracy of [11C]PIB PET and Cerebrospinal Fluid Biomarkers in a Sample of Patients with Mild Cognitive Impairment and Alzheimer's Disease.
    Leuzy A; Carter SF; Chiotis K; Almkvist O; Wall A; Nordberg A
    J Alzheimers Dis; 2015; 45(4):1077-88. PubMed ID: 25649653
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Florbetapir positron emission tomography and cerebrospinal fluid biomarkers.
    Hake A; Trzepacz PT; Wang S; Yu P; Case M; Hochstetler H; Witte MM; Degenhardt EK; Dean RA;
    Alzheimers Dement; 2015 Aug; 11(8):986-93. PubMed ID: 25916563
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Alzheimer's Disease Neuroimaging Initiative 2 Biomarker Core: A review of progress and plans.
    Kang JH; Korecka M; Figurski MJ; Toledo JB; Blennow K; Zetterberg H; Waligorska T; Brylska M; Fields L; Shah N; Soares H; Dean RA; Vanderstichele H; Petersen RC; Aisen PS; Saykin AJ; Weiner MW; Trojanowski JQ; Shaw LM;
    Alzheimers Dement; 2015 Jul; 11(7):772-91. PubMed ID: 26194312
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.